Tropomyosin receptor kinase B

Function

Tropomyosin receptor kinase B is the high-affinity catalytic receptor for several "neurotrophins", small protein growth factors that induce the survival and differentiation of distinct cell populations. The neurotrophins that activate TrkB are: BDNF (Brain Derived Neurotrophic Factor), neurotrophin-4 (NT-4), and neurotrophin-3 (NT-3). As such, TrkB mediates the multiple effects of these neurotrophic factors, which include neuronal differentiation and survival.

The TrkB receptor is part of the large family of receptor tyrosine kinases. A tyrosine kinase is an enzyme capable of adding a phosphate group to certain tyrosines on target proteins or substrates. A receptor tyrosine kinase is a tyrosine kinase located at the cellular membrane, and is activated by the binding of a ligand to the receptor's extracellular domain. Other examples of tyrosine kinase receptors include the insulin receptor, the IGF1 receptor, the MuSK protein receptor, the Vascular Endothelial Growth Factor (or VEGF) receptor, etc.

Currently, there are three TrkB isoforms in the mammalian CNS. The full-length isoform (TK+) is a typical tyrosine kinase receptor and transduces the BDNF signal via Ras-ERK, PI3K, and PLCγ. In contrast, two truncated isoforms (TK-: T1 and T2) possess the same extracellular domain, transmembrane domain, and first 12 intracellular amino acid sequences as TK+. However, the C-terminal sequences are isoform-specific (11 and 9 amino acids, respectively).

BDNF binding initiates TrkB dimerization and trans-autophosphorylation, revealing binding sites for PLCγ and Shc proteins. When PLCγ binds to TrkB, PIP2 is hydrolyzed into IP3 and DAG. IP3 binds to the endoplasmic reticulum, inducing calcium release, while DAG stimulates Protein Kinase C (PKC). PKC activation is implicated in neuronal plasticity and survival, among other effects. Shc binding recruits PI3K, which promotes AKT and MAPK/ERK signaling cascades involved in dendritogenesis, cellular differentiation, and proliferation.

TrkB.T1 isoforms prevent autophosphorylation, limiting full-length TrkB signaling and its associated effects on neuronal plasticity. However, TrkB.T1 has separate signaling pathways in astrocytes and glial cells, regulating calcium influx and cell morphology. Disease states associated with overexpression of TrkB.T1 include ischemia, stroke, spinal cord injury, neurodegenerative disorders, and chronic pain.

Family members

TrkB is part of a sub-family of protein kinases which includes also TrkA and TrkC. There are other neurotrophic factors structurally related to BDNF: NGF (for nerve growth factor), NT-3 (for neurotrophin-3) and NT-4 (for neurotrophin-4). While TrkB mediates the effects of BDNF, NT-4 and NT-3, TrkA is bound and thereby activated only by NGF. Further, TrkC binds and is activated by NT-3.

TrkB binds BDNF and NT-4 more strongly than it binds NT-3. NT-3 has a greater binding affinity for TrkC than TrkB.

Clinical Implications

Cancer

Although originally identified as an oncogenic fusion in 1982, only recently has there been a renewed interest in the Trk family as it relates to its role in human cancers because of the identification of NTRK1 (TrkA), NTRK2 (TrkB) and NTRK3 (TrkC) gene fusions and other oncogenic alterations in a number of tumor types. A number of Trk inhibitors are (in 2015) in clinical trials and have shown early promise in shrinking human tumors.

Neurodegenerative Diseases

TrkB and its ligand BDNF have been associated to both normal brain function and in the pathology and progression of Alzheimer's disease (AD) and other neurodegenerative disorders. First of all, BDNF/TrkB signalling has been implicated in long-term memory formation, the regulation of long-term potentiation, as well as hippocampal synaptic plasticity. In particular, neuronal activity has been shown to lead to an increase in TrkB mRNA transcription, as well as changes in TrkB protein trafficking, including receptor endocytosis or translocation. Both TrkB and BDNF are downregulated in the brain of early AD patients with mild cognitive impairments, while work in mice has shown that reducing TrkB levels in the brain of AD mouse models leads to a significant increase in memory deficits. In addition, combining the induction of adult hippocampal neurogenesis and increasing BDNF levels lead to an improved cognition, mimicking exercise benefits in AD mouse models. The effect of TrkB/BDNF signalling on AD pathology has been shown to be in part mediated by an increase in δ-secretase levels, via an upregulation of the JAK2/STAT3 pathway and C/EBPβ downstream of TrkB. Additionally, TrkB has been shown to reduce amyloid-β production by APP binding and phosphorylation, while TrkB cleavage by δ-secretase blocks normal TrkB activity. Dysregulation of the TrkB/BDNF pathway has been implicated in other neurological and neurodegenerative conditions, including stroke, Huntington's Disease, Parkinson's Disease, Amyotrophic lateral sclerosis and stress-related disorders.

Epilepsy

TrkB activation is implicated in KCC2 downregulation in the CNS. KCC2 cotransports potassium and chloride ions out of the cell. Chloride levels inside the cell remain low, so when GABAA receptors are activated, extracellular chloride can flow into the cell, inducing hyperpolarization. KCC2 downregulation causes intracellular Cl- accumulation, decreasing the electrochemical gradient that is critical for inhibitory GABAA signaling. Altered inhibitory transmission caused by KCC2 downregulation is one mechanism implicated in epilepsy.

Depression

In the early 2020s, it was reported that some antidepressants, ketamine, and certain psychedelic drugs including LSD and psilocin interacted directly with TrkB and that this action might be involved in their antidepressant effects. However, subsequent studies with LSD and psilocin failed to reproduce these findings and instead found no interaction of these agents with TrkB.

Drug Targets

Entrectinib (formerly RXDX-101) is an investigational drug developed by Ignyta, Inc., which has potential antitumor activity. It is a selective pan-Trk receptor tyrosine kinase inhibitor (TKI) targeting gene fusions in TrkA, TrkB (this gene), and TrkC (respectively, coded by NTRK1, NTRK2, and NTRK3 genes) that is currently in phase 2 clinical testing. In addition, TrkB/BDNF signalling has been the target for developing novel drugs for Alzheimer's Disease, Parkinson's Disease or other neurodegenerative and psychiatric disorders, aiming at either pharmacological modulation of the pathway (e.g. small molecule mimetics) or other means (e.g. exercise induced changes in TrkB signalling).

Ligands

Agonists

• 3,7-Dihydroxyflavone
• 3,7,8,2'-Tetrahydroxyflavone
• 7,3′-Dihydroxyflavone
• 7,8,2'-Trihydroxyflavone
• 7,8,3'-Trihydroxyflavone
• Amitriptyline
• BNN-20
• BrAD-R13 (Braegen-01)
• Braegen-02
• Brain-derived neurotrophic factor (BDNF)
• Deoxygedunin
• Diosmetin
• DMAQ-B1
• Eutropoflavin (4'-DMA-7,8-DHF)
• HIOC
• LM22A-4
• N-Acetylserotonin (NAS)
• Neurotrophin-3 (NT-3)
• Neurotrophin-4 (NT-4)
• Norwogonin (5,7,8-THF)
• R7 (prodrug of tropoflavin)
• R13 (prodrug of tropoflavin)
• TDP6
• Tropoflavin (7,8-DHF)

Antagonists

• ANA-12
• Cyclotraxin B
• Gossypetin (3,5,7,8,3',4'-HHF)

Positive allosteric modulators

• ACD856 (nanomolar range)
• Ponazuril (ACD855) (micromolar range)

Antidepressants like fluoxetine, imipramine, and others (micromolar range), dissociatives and related compounds like ketamine (micromolar range) and (2R,6R)-hydroxynorketamine (nanomolar range), and serotonergic psychedelics and related drugs like LSD, psilocin, and lisuride (nanomolar range) have all been reported to act as positive allosteric modulators of TrkB. However, subsequent studies with LSD and psilocin failed to replicate these findings and instead found no interactions of these drugs with TrkB.

Others

• Dehydroepiandrosterone (DHEA)

Interactions

TrkB has been shown to interact with:

• Brain-derived neurotrophic factor (BDNF),
• FYN,
• NCK2,
• PLCG1,
• Sequestosome 1, and
• SHC3.

References

References

1. (December 1989). "trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development". The EMBO Journal.
2. (February 1993). "Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells". Neuron.
3. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
4. (January 1995). "Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2)". Genomics.
5. (May 1991). "trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor". Cell.
6. (July 1991). "TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor". Cell.
7. (December 2019). "The Impact of Kinases in Amyotrophic Lateral Sclerosis at the Neuromuscular Synapse: Insights into BDNF/TrkB and PKC Signaling". Cells.
8. (2024). "Jasper's basic mechanisms of the epilepsies". Oxford University Press.
9. (2020-05-11). "Function and Mechanisms of Truncated BDNF Receptor TrkB.T1 in Neuropathic Pain". [[cell (journal).
10. (June 2001). "Trk receptors: mediators of neurotrophin action". Current Opinion in Neurobiology.
11. (December 1982). "Oncogenes in solid human tumours". Nature.
12. (October 2015). "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101". Cancer Discovery.
13. (December 2009). "TrkB signalling pathways in LTP and learning". Nature Reviews. Neuroscience.
14. (November 2004). "Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF". Ageing Research Reviews.
15. (September 2005). "Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications". Trends in Neurosciences.
16. (November 2010). "Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression". Biological Psychiatry.
17. (June 2005). "Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease". Journal of Neurochemistry.
18. (May 2015). "TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice". Translational Psychiatry.
19. (September 2018). "Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer's mouse model". Science.
20. (July 2019). "Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer's Disease". Cell Reports.
21. (July 2021). "TrkB receptor cleavage by delta-secretase abolishes its phosphorylation of APP, aggravating Alzheimer's disease pathologies". Molecular Psychiatry.
22. (October 2020). "Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders". Molecular Psychiatry.
23. (2019-08-13). "The Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis". Frontiers in Cellular Neuroscience.
24. (January 2017). "Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies". International Journal of Molecular Sciences.
25. (March 2010). "Downregulation of potassium chloride cotransporter KCC2 after transient focal cerebral ischemia". Stroke.
26. (March 2021). "Antidepressant drugs act by directly binding to TRKB neurotrophin receptors". Cell.
27. (June 2023). "Psychedelics promote plasticity by directly binding to BDNF receptor TrkB". Nature Neuroscience.
28. (October 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics". Neuron.
29. (18 April 2016). "Promising entrectinib clinical trial data". ScienceDaily.
30. (March 2020). "Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer's Disease". CNS Drugs.
31. (February 2020). "BDNF as a Promising Therapeutic Agent in Parkinson's Disease". International Journal of Molecular Sciences.
32. (June 2009). "Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity". Chemistry & Biology.
33. (April 2011). "Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis". PLoS Biology.
34. (July 2010). "Deoxygedunin, a natural product with potent neurotrophic activity in mice". PLOS ONE.
35. (December 2010). "A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect". Journal of Medicinal Chemistry.
36. (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration.
37. (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America.
38. (October 2015). "7,8-Dihydroxyflavone reduces sleep during dark phase and suppresses orexin A but not orexin B in mice". Journal of Psychiatric Research.
39. (July 2021). "Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction". Cells.
40. (April 2016). "Novel mechanisms for DHEA action". Journal of Molecular Endocrinology.
41. (January 2015). "Dehydroepiandrosterone: an ancestral ligand of neurotrophin receptors". Endocrinology.
42. (October 1997). "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking". The Journal of Biological Chemistry.
43. (March 2002). "A discrete domain of the human TrkB receptor defines the binding sites for BDNF and NT-4". Biochemical and Biophysical Research Communications.
44. (July 1998). "Association of the Src family tyrosine kinase Fyn with TrkB". Journal of Neurochemistry.
45. (June 2002). "Brain-derived neurotrophic factor promotes interaction of the Nck2 adaptor protein with the TrkB tyrosine kinase receptor". Biochemical and Biophysical Research Communications.
46. (April 1999). "The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation". The Journal of Biological Chemistry.
47. (February 2003). "Association of the atypical protein kinase C-interacting protein p62/ZIP with nerve growth factor receptor TrkA regulates receptor trafficking and Erk5 signaling". The Journal of Biological Chemistry.
48. (March 1998). "N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling". The Journal of Biological Chemistry.